北美分子即时诊断检测（使用 NAAT）、产品（仪器、耗材和试剂）、适应症（呼吸道感染检测、性传播感染 (STI)检测、胃肠道感染检测及其他）、最终用户（实验室、医院、诊所、家庭护理、门诊中心、辅助生活设施及其他）、检测方式（处方检测和 OTC 检测）、分销渠道（直销、第三方分销商、在线销售）、国家（美国和加拿大）、行业趋势和预测（至 2028 年）
市场分析和见解：北美分子即时诊断检测（使用 NAAT）市场
北美分子即时诊断（使用 NAAT）市场规模预计将从 2020 年的 127.114 亿美元增至 2028 年的 347.3647 亿美元，在 2021 年至 2028 年的预测期内，复合年增长率为 12.1%。
POCT 的特点是可以在患者附近进行的检测，可以立即做出医疗决策，包括结果和监测。现在进入临床使用的 POCT 设备基于核酸扩增技术 (NAAT)，本文将其定义为第二代设备。与第一代 POCT 相比，这些平台的灵敏度通常有所提高，通常在 60% 到 90% 之间，并且需要便携式仪器，占地面积约为 30 厘米 x 30 厘米。这些仪器主要用于通过 NAAT 技术对各种疾病（如HIV、HPV 和呼吸系统疾病）进行分子检测。NAAT 是核酸扩增技术，通过检测病原体 DNA 或 RNA 可以识别病原体。
- 在全球大流行中，为了协同 NAAT 的敏感性和 POCT 检测的易用性，设计了基于 NAAT 的微型 POCT 设备和检测，以更快地筛查和诊断 COVID-19，这也推动了市场的增长。
分子即时检测的显著优势包括快速诊断过程、治疗选择、监测和预后。这也将有助于运营决策和适当的资源利用。慢性病患病率的上升和诊断率的上升预计将成为市场发展的驱动力。然而，即时检测仪器的高成本可能会阻碍市场的增长。
预计主要参与者采取的战略举措将为市场增长提供有利可图的机会。另一方面，严格的监管审批可能会对市场构成挑战
这份北美分子即时检测（使用 NAAT）市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地市场参与者的影响，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美分子即时诊断检测（使用 NAAT）市场范围和市场规模
北美分子诊断即时检测（使用 NAAT）市场根据产品、适应症、最终用户、检测模式和分销渠道分为五个显著的部分。
- 根据产品，北美分子即时检测（使用 NAAT）市场细分为仪器、耗材和试剂。2021 年，分子即时检测（使用 NAAT）市场中的耗材和试剂部分预计将增长，因为美国人口拥有广泛的产品组合，因为有许多公司为北美地区生产试剂盒和仪器。
- 根据适应症，北美分子即时检测（使用 NAAT）市场细分为性传播感染 (STI) 检测、呼吸道感染检测、胃肠道感染检测等。2021 年，由于美国人口中 COVID-19 的状况恶化，分子即时检测（使用 NAAT）市场中的呼吸道部分预计将占据主导地位。
- 根据最终用户，北美分子即时检测（使用 NAAT）市场细分为实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等。2021 年，由于美国诊断和研究质量高，分子即时检测（使用 NAAT）市场中的实验室部分预计将占据主导地位
- 根据检测方式，北美分子即时检测（使用 NAAT）市场分为处方检测和 OTC 检测。2021 年，分子即时检测（使用 NAAT）市场中的处方检测部分预计将增长，因为 NAAT 在 PCOT 中的使用尚属首次，因此需要专家建议和监控，这增加了处方检测的市场。
- 根据分销渠道，北美分子即时检测（使用 NAAT）市场细分为直接招标、第三方分销商和在线销售。2021 年，分子即时检测（使用 NAAT）市场的直销部分预计将增长，因为大多数在该市场开展业务的公司都在美国开展业务，这将增加该地区的直销。
北美分子诊断即时检测（使用 NAAT）市场国家级分析
对北美分子诊断即时检测（使用 NAAT）市场进行了分析，并按产品、适应症、最终用户、检测模式和分销渠道提供了市场规模信息。
由于拥有优秀的医疗保健基础设施，美国有望主导北美分子即时诊断（使用 NAAT）市场，这比北美地区的其他国家对分子 POCT 产品的需求更大。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
制造商推出的新产品为分子即时诊断测试（使用 NAAT）市场参与者创造了新的机会
北美分子即时检测（使用 NAAT）市场还为您提供了每个国家/地区美容行业增长的详细市场分析，包括分子即时检测（使用 NAAT）市场销售、分子即时检测（使用 NAAT）市场发展的影响以及监管情景的变化及其对北美分子即时检测（使用 NAAT）市场的支持。数据涵盖 2010 年至 2019 年的历史时期。
竞争格局和分子诊断即时检测（使用 NAAT）市场份额分析
北美分子即时检测（使用 NAAT）市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对北美分子即时检测（使用 NAAT）市场的关注有关。
在北美分子即时诊断（使用 NAAT）市场提供北美分子即时诊断（使用 NAAT）产品的主要公司有：Thermo Fisher Scientific Inc.、Hologic, Inc.、BD、F. Hoffmann-La Roche Ltd、ABBOTT、Seegene Inc.、bioMérieux SA、QIAGEN、Bio-Rad Laboratories, Inc.、PerkinElmer Inc.、Grifols, SA、Quidel Corporation、GenMark Diagnostics, Inc.、SD Biosensor, INC.、Oxford Nanopore Technologies、Wondfo、Randox Laboratories Ltd.、Meridian Bioscience、Sekisui Diagnostics、QuantuMDx Group Ltd.、Lucira Health Inc.、binx health, inc.、Sysmex（Sysmex Corporation 的子公司）、Co-Diagnostics, Inc. 等。
全球各地的公司也发起了许多产品发布和协议，这也加速了分子即时诊断（使用 NAAT）市场的发展。
例如，
- 2020 年 5 月，Bio-Rad Laboratories, Inc. 宣布，他们已获得 FDA 的 SARS-CoV-2 总抗体测试紧急使用授权 (EUA)。这是一种基于血液的免疫测定法，用于帮助临床医生确定个体是否产生了针对 SARS-CoV-2 的抗体。获得此项批准后，该公司提高了其在市场上的信誉
该公司推出的这款新产品增加了其在市场上的蛋白质估算产品组合。市场参与者的合作、合资企业和其他策略正在增强公司在分子即时检测（使用 NAAT）市场中的市场，这也为该组织改善其在北美分子即时检测（使用 NAAT）市场的产品提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES
4.3.1 CEPHEID
4.3.2 THERMO FISHER SCIENTIFIC INC.
4.3.3 HOLOGIC, INC.
4.3.4 BD
4.3.5 F. HOFFMANN-LA ROCHE LTD
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY
4.5 DISTRIBUTORS
4.5.1 NORTH AMERICA
4.5.2 EUROPE
4.5.3 SOUTH ASIA
4.5.4 SOUTH EAST ASIA
4.5.5 MIDDLE EAST
4.5.6 AFRICA
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 PANDEMIC OUTBREAK OF COVID-19
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 LACK OF ACCESSIBILITY
7 IMPACT OF COVID-19 ON THE NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19
7.5 CONCLUSION:
8 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & REAGENTS
8.3 INSTRUMENTS
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)
9 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS TESTING
9.2.1 COVID-19
9.2.2 FLU B
9.2.3 FLU A
9.2.4 RSV
9.2.5 TUBERCULOSIS
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)
9.2.7 OTHERS
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING
9.3.1 TV
9.3.2 CT
9.3.3 NG
9.3.4 HPV
9.3.5 HSV
9.3.6 MG
9.3.7 UU
9.3.8 MH
9.3.9 OTHERS
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING
9.4.1 GROUP B STREPTOCOCCUS
9.4.2 SHIGA TOXIN
9.4.3 H. PYLORI
9.5 OTHERS
10 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER
10.1 OVERVIEW
10.2 LABORATORIES
10.2.1 POLYMERASE CHAIN REACTION
10.2.2 ISOTHERMAL AMPLIFICATION
10.3 HOSPITAL
10.3.1 POLYMERASE CHAIN REACTION
10.3.2 ISOTHERMAL AMPLIFICATION
10.4 CLINICS
10.4.1 POLYMERASE CHAIN REACTION
10.4.2 ISOTHERMAL AMPLIFICATION
10.5 AMBULATORY CENTER
10.5.1 POLYMERASE CHAIN REACTION
10.5.2 ISOTHERMAL AMPLIFICATION
10.6 HOMECARE
10.6.1 POLYMERASE CHAIN REACTION
10.6.2 ISOTHERMAL AMPLIFICATION
10.7 ASSISTED LIVING FACILITIES
10.7.1 POLYMERASE CHAIN REACTION
10.7.2 ISOTHERMAL AMPLIFICATION
10.8 OTHERS
11 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING
11.1 OVERVIEW
11.2 PRESCRIPTION-BASED TESTING
11.3 OTC TESTING
12 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
13 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
14 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 DANAHER
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 F.HOFFMANN-LA-ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 BINX HEALTH, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOMERIEUX SA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 CO-DIAGNOSTICS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 GENMARK DIAGNOSTICS, INC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 GRIFOLS, S.A.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 LUCIRA HEALTH INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MERIDIAN BIOSCIENCE
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 QUANTUMDX GROUP LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 QUIDEL CORPORATION
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 SD BIOSENSOR, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 WONDFO
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)
TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA
TABLE 8 DISTRIBUTORS ACROSS EUROPE
TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA
TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA
TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST
TABLE 12 DISTRIBUTORS ACROSS AFRICA
TABLE 13 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 62 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 63 U.S. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 65 U.S. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 66 U.S. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 67 U.S. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 68 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 69 U.S. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 70 U.S. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 71 U.S. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 72 U.S. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 U.S. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 U.S. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 76 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 77 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 78 CANADA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 79 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 80 CANADA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 81 CANADA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 82 CANADA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 83 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 CANADA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 CANADA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 CANADA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 87 CANADA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 88 CANADA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 89 CANADA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 90 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID
FIGURE 11 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD
FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
FIGURE 16 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016
FIGURE 17 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020
FIGURE 18 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 19 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 20 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020
FIGURE 22 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 25 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020
FIGURE 26 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 28 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020
FIGURE 30 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 33 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 34 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 38 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 39 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 41 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 42 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
